skip to Main Content

Overview

Symbol
ALIM

Alimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.

IR Nav

Tear Sheet IR Contacts Subscribe to News Alerts RSS Feed

Company Profile

6120 Windward Parkway, Suite 290
Alpharetta, GA 30005

1 (844) 445-8843

(678) 990 5744

info@alimerasciences.com

Today

Intraday stock chart for alim

Leadership

Rick Eiswirth

President and Chief Executive Officer

Philip Ashman

COO, Senior VP, Commercial Operations Europe

Dave Holland

CMO, Senior VP Corporate Communications & Managed Markets

Phil Jones

Chief Financial Officer

Samer Kaba M.D

Chief Medical Officer

View Management Team

Past Six Months

6 month stock chart for alim

Recent News & Filings

Alimera Sciences Corporate Presentation 10-K - Dec 31, 2018 10-Q - Sep 30, 2019

Investor Relations

John Marco, CORE IR
377 Oak Street
Garden City, NY 11530
Phone: 516-222-2560
E-mail: johnm@coreir.com
www.coreir.com

Transfer Agent

AST Financial, Bryan Anderson,
Relationship Manager
banderson@astfinancial.com

Auditors

Grant Thornton LLP
Joseph Heatherly, Partner,
Joseph.Heatherly@us.gt.com

Corporate Counsel

Charles Vaughn,
Nelson Mullins
(404) 322-6189
charles.vaughn@nelsonmullins.com

Subscribe to IR news and filing alerts

You can opt out at any time. We do not share or sell your info.

Back To Top
Skip to content